Format

Send to

Choose Destination
Expert Opin Pharmacother. 2007 Oct;8(14):2359-69.

Sunitinib.

Author information

1
Cleveland Clinic Taussig Cancer Center, Department of Solid Tumor Oncology and Urology, 9500 Euclid Avenue/Desk R35, Cleveland, Ohio 44195, USA. rinib2@ccf.org

Abstract

Sunitinib is a small-molecule inhibitor of several receptor tyrosine kinases relevant to tumor angiogenesis, including the vascular endothelial growth factor (VEGF) receptor. Potent inhibition of this related family of receptors and consequent antiangiogenic effects have been demonstrated in vitro and in murine models. Human studies have established 50 mg daily dosing given on an intermittent schedule as a tolerable dose. Significant antitumor effects have been observed, most notably in advanced renal cell carcinoma (RCC) and imatinib refractory/intolerant gastrointestinal stromal tumor (GIST). Sunitinib has received regulatory approval in these two indications, and is at present being investigated across a broad array of solid tumors. Despite these initial results, several questions remain to optimize the utility of this agent.

PMID:
17927489
DOI:
10.1517/14656566.8.14.2359
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center